Pefcalcitol clinical trials
Also written M518101.
How each study uses pefcalcitol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- M518101
- 9
Studies by the year they started
9 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 5 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Maruho North America Inc. (6) · Maruho Co., Ltd. (2) · Maruho Europe Limited (1)
Studies
Open first, then newest update. How each study uses pefcalcitol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis PatientsCompletedPhase 3Maruho Europe LimitedNCT01989429Written as M518101
- Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis PatientsCompletedPhase 2Maruho Co., Ltd.NCT01301157Written as M518101
- Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque PsoriasisCompletedPhase 3Maruho North America Inc.NCT01908595Written as M518101
- Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisCompletedPhase 3Maruho North America Inc.NCT01878461Written as M518101
- Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque PsoriasisCompletedPhase 3Maruho North America Inc.NCT01873677Written as M518101
- Skin Safety Study to Evaluate the Sensitizing Potential in Healthy VolunteersCompletedPhase 1Maruho North America Inc.NCT02256930Written as M518101
- Skin Safety Study to Evaluate the Irritation Potential in Healthy VolunteersCompletedPhase 1Maruho North America Inc.NCT02227069Written as M518101
- Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis PatientsCompletedPhase 1Maruho North America Inc.NCT01844973Written as M518101
- Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis PatientsCompletedPhase 2Maruho Co., Ltd.NCT00884169Written as M518101
Codes
What other systems call pefcalcitol · ClinicalTrials.gg INT017094
- UNII (FDA) KT5224XSHWPEFCALCITOLConfirmed FDA, Wikidata
- Wikidata Q27282425pefcalcitolConfirmed FDA, Wikidata
- NCI Thesaurus C170289PefcalcitolOne source FDA
- DrugBank DB11786One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KT5224XSHW | PEFCALCITOL | Confirmed FDA, Wikidata |
| Wikidata | Q27282425 | pefcalcitol | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170289 | Pefcalcitol | One source FDA |
| DrugBank | DB11786 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.